Cara Therapeutics (CARA) PT Lowered to $26 at Needham & Company After Endpoints Missed in Ph2 KARE Trial
Tweet Send to a Friend
Needham & Company analyst Alan Carr lowered the price target on Cara Therapeutics (NASDAQ: CARA) to $26.00 (from $35.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
